-
Closing Out the Year with Connection & Community at PPMD Together
Recently, the Duchenne and Becker community gathered virtually for the final PPMD Together meeting of
-
Avidity’s New Access Program Marks a Milestone for the Duchenne Community
In 2018, CureDuchenne was the only Duchenne-focused organization to invest in Avidity Biosciences, recognizing the potential of their
-
Finding meaning at 30 through my disease communities
Recently, my role at Shalom Medcare shifted from marketing communications assistant to brand executive. This
-
Avidity announces a Managed Access Program for del-zota, for eligible individuals with Duchenne amenable to skipping exon 44
As an early funder of Avidity Biosciences, CureDuchenne is so happy to share that Avidity
-
Avidity Biosciences Announces U.S. Managed Access Program for del-zota
Avidity Biosciences, Inc. has announced its Managed Access Program (MAP) for delpacibart zotadirsen (del-zota) for
-
Clinical Research Alert: Real World Study of Male Fertility Following Risdiplam Treatment
Researchers at Genentech Inc. are seeking adult males treated with risdiplam (Evrysdi) for spinal muscular atrophy
-
Quick Guide: Understanding Programs and Benefits for People with Disabilities
Along with the daily challenges of living with a disability, many individuals face the added
-
Becker Muscular Dystrophy Series – Part 2: Cardiopulmonary Care
The second session in PPMD’s Becker Muscular Dystrophy webinar series focused on cardiopulmonary care. Our
-
Tis the Season for Holiday Hacks and Tips
For some, the holiday season means the hustle and bustle of hosting, traveling, gift giving,
-
FDA approves new safety warning and updated prescribing information for Sarepta’s Elevidys
Letter to the community added November 17, 2025 The FDA has approved the new labeling
